ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1117

Government Subsidization of Biologic Therapy for Inflammatory Arthritis in a Co-Funded Healthcare Model: A Singapore Experience

Kai Ting Cheryl Chua1, Wai Yee Joanna Leong 2, Kee Fong Phang 1, Sajeewani Dissanayake 1, Peter Cheung 1, Warren Fong 3, Keng Hong Leong 4, Ying Ying Leung 3, Anita Yee Nah Lim 1, Nai Lee Lui 5, Mona Manghani 6, Amelia Santosa 1, Melonie Kannamma Sriranganathan 2, Ernest Suresh 7, Teck Choon Tan 8, Gim Gee Teng 1 and Manjari Lahiri 1, 1National University Health System, Singapore, Singapore, 2Changi General Hospital, Singapore, Singapore, 3Singapore General Hospital, Singapore, Singapore, 4Leong Keng Hong Arthritis and Medical Clinic, Singapore, Singapore, 5Lui Centre for Arthritis & Rheumatology, Gleneagles medical Centre, Singapore, Singapore, 6Tan Tock Seng Hospital, Singapore, Singapore, 7Ng Teng Fong Hospital, Singapore, Singapore, 8Khoo Teck Puat Hospital, Singapore, Singapore

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Biologics and inflammatory arthritis

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 11, 2019

Session Title: Health Services Research Poster II – ACR/ARP

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Real world utilization of biologic therapy for inflammatory arthritis often falls short of international best practice and is heavily influenced by affordability and national healthcare financing models. Healthcare in Singapore is delivered through a complex mix of regulated compulsory personal savings, limited hospitalization-focused personal and government aided medical insurance, and means-tested government subsidies for selected clinical indications. We describe our experience in translating current evidence into an applicable framework to guide government funding decisions to facilitate equitable access to biologic therapy.

Methods: A core working group (CWG) searched recently published guidelines of biologic agents in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA) developed for best practice use (9 RA, 5 PsA and 4 AxSpA) or reimbursement (2 RA, 4 PsA and 2 AxSpA). Where appropriate, recent primary literature was reviewed and the evidence synthesized in the form of tables. A modified Delphi approach was used and statements were drafted for rating by an expert task force panel (TFP) comprising rheumatologists practicing in the public and private sectors across Singapore. The TFP independently rated 3 separate sets of draft statements for RA, PsA and AxSpA after consideration of the synthesized evidence. Consensus was reached if there was at least 70% agreement (score of 4 or 5 on a five-point Likert scale). Statements not reaching consensus were discussed in a face to face meeting, and second round of independent voting was done, after rewording and/or editing statements if necessary. Next, government agencies were engaged to adopt the final statements to guide government funding. The guidelines will be disseminated to the relevant pharmaceutical companies to allow them to make informed decisions on drug pricing to be considered favourably in the government tender.

Results: Three sets of consensus statements were derived, pertaining to initiation, choice and continuation of biologic therapy for active RA, PsA or AxSpA (tables 1, 2, 3 respectively). These form an easily applicable framework to be used by practicing physicians and funding authorities.

Conclusion: We describe our experience in formulating evidence-based guidelines within the real-world practice which is heavily influenced by treatment affordability. Lessons learnt in engaging all relevant stakeholders may be applicable to guide nascent subsidization programs in healthcare economies worldwide.


Table 1_300519


Table 2_300519


Table 3_300519


Disclosure: K. Chua, None; W. Leong, None; K. Phang, None; S. Dissanayake, None; P. Cheung, Novartis, 2; W. Fong, Abbvie, 5, Novartis, 8; K. Leong, None; Y. Leung, Pfizer, 2, 8, Boehringer, 8, Abbvie, 9; A. Lim, None; N. Lui, Pfizer, 5; M. Manghani, None; A. Santosa, Pfizer, 9; M. Sriranganathan, Pfizer, 9, Amgen, 9, Abbvie, 9; E. Suresh, None; T. Tan, Pfizer, 9; G. Teng, Abbvie, 9; M. Lahiri, Elli Lilly, 5, Pfizer, 9, Novartis, 9.

To cite this abstract in AMA style:

Chua K, Leong W, Phang K, Dissanayake S, Cheung P, Fong W, Leong K, Leung Y, Lim A, Lui N, Manghani M, Santosa A, Sriranganathan M, Suresh E, Tan T, Teng G, Lahiri M. Government Subsidization of Biologic Therapy for Inflammatory Arthritis in a Co-Funded Healthcare Model: A Singapore Experience [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/government-subsidization-of-biologic-therapy-for-inflammatory-arthritis-in-a-co-funded-healthcare-model-a-singapore-experience/. Accessed April 13, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/government-subsidization-of-biologic-therapy-for-inflammatory-arthritis-in-a-co-funded-healthcare-model-a-singapore-experience/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.